The IL-33/ILC2 axis has shown to drive anti-tumor responses in melanoma [60,61,151] and orthotopic pancreatic tumors [62], and we have described the effect of IL-33 in combination with PD-1 blockade to significantly increase the anti-melanoma response [60]. This evidence concerns the gene PDCD1 and neoplasm.